These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 17519075)

  • 41. Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE).
    Blauvelt A; Prinz JC; Gottlieb AB; Kingo K; Sofen H; Ruer-Mulard M; Singh V; Pathan R; Papavassilis C; Cooper S;
    Br J Dermatol; 2015 Feb; 172(2):484-93. PubMed ID: 25132411
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Infliximab monotherapy in Japanese patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. A randomized, double-blind, placebo-controlled multicenter trial.
    Torii H; Nakagawa H;
    J Dermatol Sci; 2010 Jul; 59(1):40-9. PubMed ID: 20547039
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials.
    Reich K; Papp KA; Blauvelt A; Tyring SK; Sinclair R; Thaçi D; Nograles K; Mehta A; Cichanowitz N; Li Q; Liu K; La Rosa C; Green S; Kimball AB
    Lancet; 2017 Jul; 390(10091):276-288. PubMed ID: 28596043
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy, Safety and Pharmacokinetics of IL-17 Monoclonal Antibody Injection (AK111) in Patients with Moderate-to-Severe Plaque Psoriasis: A Randomized, Double-Blinded, Placebo-Controlled Phase Ib Multidose Escalation Clinical Study.
    Jiang C; Zhou H; Zhang W; Xia Y; Li B; Ni X; Wang G; Zhang W; Chen B; He Z; Zhang M; Chen R; Jin H; Deng L
    Dermatol Ther (Heidelb); 2023 Feb; 13(2):555-567. PubMed ID: 36566344
    [TBL] [Abstract][Full Text] [Related]  

  • 45. CLinical experience acquired with the efalizumab (Raptiva) (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from a phase III international randomized, placebo-controlled trial.
    Dubertret L; Sterry W; Bos JD; Chimenti S; Shumack S; Larsen CG; Shear NH; Papp KA;
    Br J Dermatol; 2006 Jul; 155(1):170-81. PubMed ID: 16792770
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial.
    Blauvelt A; Papp KA; Griffiths CE; Randazzo B; Wasfi Y; Shen YK; Li S; Kimball AB
    J Am Acad Dermatol; 2017 Mar; 76(3):405-417. PubMed ID: 28057360
    [TBL] [Abstract][Full Text] [Related]  

  • 47. First-in-human study demonstrating the safety and clinical efficacy of novel anti-IL-17A monoclonal antibody CJM112 in moderate to severe plaque psoriasis.
    Kaul M; Jarvis P; Rozenberg I; Kolbinger F; Di Padova F; Calonder C; Espie P; Rondeau JM; Cebe R; Huber T; Mussmann R; Aassi M; Sligh TS
    J Eur Acad Dermatol Venereol; 2021 May; 35(5):1143-1151. PubMed ID: 33617042
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis.
    Menter A; Gordon KB; Leonardi CL; Gu Y; Goldblum OM
    J Am Acad Dermatol; 2010 Sep; 63(3):448-56. PubMed ID: 20605254
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Efficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis: results from a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison study.
    Papp KA; Kaufmann R; Thaçi D; Hu C; Sutherland D; Rohane P
    J Eur Acad Dermatol Venereol; 2013 Mar; 27(3):e376-83. PubMed ID: 23030767
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis.
    Gordon KB; Duffin KC; Bissonnette R; Prinz JC; Wasfi Y; Li S; Shen YK; Szapary P; Randazzo B; Reich K
    N Engl J Med; 2015 Jul; 373(2):136-44. PubMed ID: 26154787
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial.
    Mease PJ; Gladman DD; Ritchlin CT; Ruderman EM; Steinfeld SD; Choy EH; Sharp JT; Ory PA; Perdok RJ; Weinberg MA;
    Arthritis Rheum; 2005 Oct; 52(10):3279-89. PubMed ID: 16200601
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study.
    van Vollenhoven RF; Hahn BH; Tsokos GC; Wagner CL; Lipsky P; Touma Z; Werth VP; Gordon RM; Zhou B; Hsu B; Chevrier M; Triebel M; Jordan JL; Rose S
    Lancet; 2018 Oct; 392(10155):1330-1339. PubMed ID: 30249507
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial.
    Choy EH; Isenberg DA; Garrood T; Farrow S; Ioannou Y; Bird H; Cheung N; Williams B; Hazleman B; Price R; Yoshizaki K; Nishimoto N; Kishimoto T; Panayi GS
    Arthritis Rheum; 2002 Dec; 46(12):3143-50. PubMed ID: 12483717
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study.
    Kavanaugh A; McInnes I; Mease P; Krueger GG; Gladman D; Gomez-Reino J; Papp K; Zrubek J; Mudivarthy S; Mack M; Visvanathan S; Beutler A
    Arthritis Rheum; 2009 Apr; 60(4):976-86. PubMed ID: 19333944
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study.
    Segal BM; Constantinescu CS; Raychaudhuri A; Kim L; Fidelus-Gort R; Kasper LH;
    Lancet Neurol; 2008 Sep; 7(9):796-804. PubMed ID: 18703004
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: results of the randomized phase 3 CADMUS study.
    Landells I; Marano C; Hsu MC; Li S; Zhu Y; Eichenfield LF; Hoeger PH; Menter A; Paller AS; Taieb A; Philipp S; Szapary P; Randazzo B
    J Am Acad Dermatol; 2015 Oct; 73(4):594-603. PubMed ID: 26259989
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Anti-E-selectin is ineffective in the treatment of psoriasis: a randomized trial.
    Bhushan M; Bleiker TO; Ballsdon AE; Allen MH; Sopwith M; Robinson MK; Clarke C; Weller RP; Graham-Brown RA; Keefe M; Barker JN; Griffiths CE
    Br J Dermatol; 2002 May; 146(5):824-31. PubMed ID: 12000379
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Secukinumab administration by autoinjector maintains reduction of plaque psoriasis severity over 52 weeks: results of the randomized controlled JUNCTURE trial.
    Lacour JP; Paul C; Jazayeri S; Papanastasiou P; Xu C; Nyirady J; Fox T; Papavassilis C
    J Eur Acad Dermatol Venereol; 2017 May; 31(5):847-856. PubMed ID: 28111801
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Long-term efficacy and safety of secukinumab in Japanese patients with moderate to severe plaque psoriasis: 3-year results of a double-blind extension study.
    Okubo Y; Ohtsuki M; Morita A; Yamaguchi M; Shima T; Tani Y; Nakagawa H;
    J Dermatol; 2019 Mar; 46(3):186-192. PubMed ID: 30672623
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Secukinumab is superior to fumaric acid esters in treating patients with moderate-to-severe plaque psoriasis who are naive to systemic treatments: results from the randomized controlled PRIME trial.
    Sticherling M; Mrowietz U; Augustin M; Thaçi D; Melzer N; Hentschke C; Kneidl J; Sieder C; Reich K
    Br J Dermatol; 2017 Oct; 177(4):1024-1032. PubMed ID: 28580646
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.